A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
SANUWAVE Health, Inc.
SNWV
$51M
Mkt Cap
$5.93
+0.17%
SANUWAVE Health, Inc. (SNWV) has a 5-year average return on invested capital (ROIC) of -22.9%. This is below average and may indicate limited pricing power.
SANUWAVE Health, Inc. (SNWV) has a market capitalization of $51M. It is classified as a small-cap stock.
SANUWAVE Health, Inc. (SNWV) does not currently pay a regular dividend.
SANUWAVE Health, Inc. (SNWV) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
SANUWAVE Health, Inc. (SNWV) reported annual revenue of $44 million in its most recent fiscal year, based on SEC EDGAR filings.
SANUWAVE Health, Inc. (SNWV) has a net profit margin of 26.8%. This is a strong margin indicating high profitability.
SANUWAVE Health, Inc. (SNWV) generated $2 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Table of Contents Sanuwave is a medical device company providing directed energy products into the wound care space. Our mission is to improve patient lives and outcomes by developing and marketing effective, easy to use products to decrease wound burden, lessen healing times, and reduce patient pain. Our focus is regenerative medicine utilizing noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. The Company’s patented and FDA cleared products include the UltraMIST® system (UM) and the PACE® family of products, both of which are used to treat a variety of acute and chronic wounds. These products are backed by an intellectual property (“IP”) portfolio of over 165 patents. In the year ended December 31, 2024, we had total revenues of $32.6 million, a 60% increase from revenues of $20.4 million in the year ended December 31, 2023.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 44M | 44M | 33M | 20M | 17M | - |
| Net Income | 12M | 12M | -33M | -26M | -10M | -27M |
| EPS | $1.38 | $1.38 | $-7.41 | $-1,682.22 | $-1.38 | $-3.45 |
| Free Cash Flow | 1.9M | 1.9M | 2.0M | -4.5M | -18M | -6.9M |
| ROIC | 13.1% | 14.6% | 14.6% | - | -45.0% | -76.0% |
| Gross Margin | 77.1% | 77.1% | 75.2% | 70.4% | 74.1% | - |
| Debt/Equity | 0.00 | -1.09 | -1.61 | -0.16 | -0.49 | -0.68 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | 4.9M | 4.9M | 3.8M | - | -9.0M | -14M |
| Operating Margin | 11.2% | 11.2% | 11.8% | - | -53.5% | - |
| ROE | 0.0% | -64.5% | 109.7% | 60.3% | 25.7% | 103.5% |
| Shares Outstanding | 9M | 9M | 4M | 0M | 7M | 8M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 17M | 20M | 33M | 44M | 44M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 74.1% | 70.4% | 75.2% | 77.1% | 77.1% |
| R&D | 3.0M | 2.2M | 1.1M | 1.3M | 982K | 1.2M | 1.2M | 1.1M | 567K | 579K | 673K | 1.4M | 1.4M |
| SG&A | 3.3M | 2.7M | 2.7M | 3.0M | 6.8M | 6.4M | 14M | 12M | 13M | 8.7M | 13M | 19M | 19M |
| EBIT | -6.0M | -4.4M | -3.3M | -3.8M | -7.2M | -8.8M | -25M | -14M | -9.0M | N/A | 3.8M | 4.9M | 4.9M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -53.5% | N/A | 11.8% | 11.2% | 11.2% |
| Net Income | -6.0M | -4.8M | -6.4M | -5.5M | -12M | -10M | -31M | -27M | -10M | -26M | -33M | 12M | 12M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -61.5% | -126.5% | -101.4% | 26.8% | 26.8% |
| Non-Recurring | 0 | 100K | 2K | 0 | 0 | 0 | 7.2M | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | -101.0% | N/M | N/M | N/M | N/M | N/M | -109.4% | -76.0% | -45.0% | N/A | 14.6% | 14.6% | 13.1% |
| ROE | 155.6% | 129.5% | 100.7% | 66.0% | 92.2% | 82.1% | 260.2% | 103.5% | 25.7% | 60.3% | 109.7% | -64.5% | 0.0% |
| ROA | -191.0% | -171.0% | -656.0% | -485.0% | -947.0% | -457.5% | -234.3% | -130.9% | -53.5% | -122.1% | -125.9% | 35.0% | 31.6% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -6.7M | -3.5M | -3.2M | -1.5M | -3.6M | -6.4M | -13M | -6.4M | -17M | -4.5M | 2.5M | 3.9M | 3.9M |
| Free Cash Flow | -6.7M | -3.5M | -3.2M | -1.5M | -3.7M | -6.5M | -13M | -6.9M | -18M | -4.5M | 2.0M | 1.9M | 1.9M |
| Owner Earnings | -7.1M | -4.3M | -4.1M | -2.3M | -6.1M | -6.8M | -13M | -7.6M | -20M | -5.6M | 153K | -1.9M | -1.9M |
| CapEx | 9K | 0 | 10K | 0 | 43K | 54K | 53K | 529K | 332K | 0 | 490K | 1.9M | 1.9M |
| Maint. CapEx | 321K | 310K | 327K | 24K | 22K | 71K | 299K | 1.2M | 952K | 1.0M | 788K | 974K | 974K |
| Growth CapEx | 0 | N/A | 0 | N/A | 21K | 0 | 0 | 0 | 0 | N/A | 0 | 968K | 968K |
| D&A | 321K | 310K | 327K | 24K | 22K | 71K | 299K | 1.2M | 952K | 1.0M | 788K | 974K | 974K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 20.0% | N/A | 50.1% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 135K | 505K | 548K | 768K | 2.5M | 333K | 22K | 0 | 1.5M | 0 | 1.5M | 4.9M | 4.9M |
| Debt Repayment | 450K | 0 | 210K | 40K | 0 | 0 | 5.5M | 493K | 3.0M | 0 | 0 | 371K | 371K |
| Balance Sheet | |||||||||||||
| Net Debt | -3.5M | 4.7M | 5.3M | -275K | 1.5M | -421K | 15M | 26M | 19M | 5.3M | 15M | 11M | 11M |
| Cash & Equiv. | 3.5M | 153K | 134K | 730K | 365K | 1.8M | 2.4M | 619K | 1.2M | 1.8M | 10M | 12M | 12M |
| Long-Term Debt | 90K | 4.8M | 5.4M | 0 | 0 | 271K | 143K | 875K | 2.9M | 0 | 66K | 16M | 16M |
| Debt/Equity | -0.06 | -0.82 | -0.78 | -0.05 | -0.12 | -0.13 | -1.25 | -0.68 | -0.49 | -0.16 | -1.61 | -1.09 | 0.00 |
| Interest Coverage | -13.7 | -11.1 | -3.9 | -3.4 | -1.6 | -4.8 | -12.4 | -2.1 | -0.7 | N/A | 0.3 | N/A | N/A |
| Equity | -1.6M | -5.9M | -6.9M | -9.9M | -15M | -10M | -14M | -39M | -41M | -45M | -16M | -21M | -21M |
| Total Assets | 4.7M | 958K | 1.0M | 1.3M | 1.2M | 3.4M | 23M | 19M | 20M | 22M | 30M | 37M | 37M |
| Total Liabilities | 6.2M | 6.8M | 7.9M | 11M | 17M | 13M | 37M | 58M | 61M | 67M | 46M | 58M | 58M |
| Intangibles | 614K | 307K | 0 | 0 | N/A | 0 | 6.5M | 5.8M | 5.1M | 4.4M | 3.7M | 3.0M | 3.0M |
| Retained Earnings | -88M | -93M | -99M | -105M | -117M | -126M | -157M | -184M | -194M | -220M | -254M | -243M | -243M |
| Working Capital | -2.2M | -852K | -7.0M | -10.0M | -15M | -9.9M | -28M | -52M | -54M | -55M | -27M | 6.8M | 6.8M |
| Current Assets | 4.0M | 636K | 914K | 1.2M | 1.1M | 2.5M | 7.9M | 4.4M | 6.6M | 9.8M | 18M | 25M | 25M |
| Current Liabilities | 6.2M | 1.5M | 7.9M | 11M | 16M | 12M | 36M | 56M | 60M | 65M | 45M | 18M | 18M |
| Per Share Data | |||||||||||||
| EPS | -8.28 | -5.52 | -4.14 | -2.76 | -5.52 | -3.45 | -5.52 | -3.45 | -1.38 | -1,682.22 | -7.41 | 1.38 | 1.38 |
| Owner EPS | -9.89 | -4.92 | -2.62 | -1.16 | -2.91 | -2.25 | -2.33 | -0.97 | -2.63 | -362.82 | 0.03 | -0.23 | -0.23 |
| Book Value | -2.15 | -6.75 | -4.44 | -4.92 | -7.29 | -3.33 | -2.45 | -4.93 | -5.50 | -2,903.65 | -3.54 | -2.42 | -2.42 |
| Cash Flow/Share | -9.26 | -3.99 | -2.06 | -0.76 | -1.72 | -2.12 | -2.27 | -0.81 | -2.30 | -295.81 | 0.55 | 0.45 | 1.49 |
| Dividends/Share | N/A | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | 0.7M | 0.9M | 1.6M | 2.0M | 2.1M | 3.0M | 5.6M | 7.9M | 7.5M | 0.0M | 4.5M | 8.6M | 8.6M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 4.3 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 52.1 | N/A | 26.3 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 12.5 |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 2.8 | N/A | 1.2 |
| FCF Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.9% | N/A | 3.8% |
| Market Cap | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 102M | 0 | 51M |
| Avg. Price | N/A | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 20.31 | 0.00 | 5.93 |
| Year-End Price | N/A | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 22.95 | 0.00 | 5.93 |
SANUWAVE Health, Inc. passes 3 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 74.2%.
SANUWAVE Health, Inc. (SNWV) reported earnings per share (EPS) of $1.38 in its most recent fiscal year.
SANUWAVE Health, Inc. (SNWV) has a return on equity (ROE) of -64.5%. A negative ROE may indicate losses or negative equity.
SANUWAVE Health, Inc. (SNWV) has a 5-year average gross margin of 74.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for SANUWAVE Health, Inc. (SNWV), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
SANUWAVE Health, Inc. (SNWV) has a book value per share of $-2.42, based on its most recent annual SEC filing.